ALA Photodynamic Therapy data

DUSA announced positive results of a Phase II trial of its topical photodynamic therapy in patients with precancerous actinic keratosis of the face and scalp. The study represents the first use of DUSA's non-laser blue light source.

Of 36 patients for whom data were available at the optimal light dosage, 90 percent of treated lesions cleared completely after a single treatment. Remaining lesions cleared after a second treatment. The placebo response rate was 26 percent. ...